NCT06276127View on ClinicalTrials.gov

Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter With Rapid Ventricular Rate.

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

June 30, 2027

Conditions
Atrial Fibrillation With Rapid Ventricular ResponseAtrial Flutter With Rapid Ventricular Response
Interventions
DRUG

Oral Bisoprolol

Participants in this group will receive a single oral dose of Bisoprolol, set at a dosage of 5 mg, with a maximum dose limit of 5 mg.

DRUG

Intravenous Diltiazem

Participants in this group will be administered a single intravenous dose of diltiazem at a dosage of 0.25 mg/kg, with a maximum dose capped at 30 mg.

Trial Locations (1)

38

Sultan Qaboos University Hospital, Muscat

All Listed Sponsors
lead

Oman Medical Speciality Board

OTHER_GOV